Elagolix, a Novel, Orally Bioavailable GnRH Antagonist under Investigation for the Treatment of Endometriosis-Related Pain
| Autor: | Bruce R. Carr, Mohammad Ezzati |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Hydrocarbons
Fluorinated Medical treatment business.industry medicine.drug_class GnRH Antagonist Endometriosis Pain General Medicine Pharmacology medicine.disease Bioavailability Gonadotropin-Releasing Hormone Clinical trial Pyrimidines Hormonal contraception Estrogen medicine Drug Evaluation Humans Female business hormones hormone substitutes and hormone antagonists Menstrual blood |
| Zdroj: | Women's Health. 11:19-28 |
| ISSN: | 1745-5065 |
| Popis: | Suppression of estrogen production and reduction of menstrual blood flow are the mainstays of medical treatment of endometriosis-related pain and have been traditionally achieved by methods such as combined hormonal contraception, progestins and GnRH analogs, all with comparable efficacies, though different side-effect profiles. Elagolix is the frontrunner among an emerging class of GnRH antagonists, which unlike their peptide predecessors has a nonpeptide structure resulting in its oral bioavailability. Phase I and II clinical trials have demonstrated safety of elagolix and its efficacy in partial and reversible suppression of ovarian estrogen production resulting in improvements in endometriosis-related pain. Phase III clinical trials are currently underway and elagolix may become a valuable addition to the armamentarium of pharmacological agents to treat endometriosis-related pain. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|